Earlier studies have shown that MITF is a direct target of miR-137, and miR-137-targeting of MITF regulates drug sensitivity in myeloma cells by reducing c-MET expression and suppressing AKT phosphorylation, accompanied by an increase in p53 expression28. Here, MITF is linked to plasma cell myeloma.